Tsingke Biotech Illuminates Future of Oligonucleotide Drugs at Shanghai Salon

On June 30, 2026, Tsingke Biotech hosted an enlightening event, the Oligonucleotide Drug Salon, at the Hilton Shanghai Zhangjiang. This occasion convened a diverse group of industry professionals, including academics, biopharmaceutical executives, and investment representatives, all eager to delve into the progressive landscape of oligonucleotide therapeutics.

The global nucleic acid medicine sector has experienced remarkable growth, thanks to breakthroughs in chemistry and delivery systems. At this salon, experts shared insights on technological innovations, regulatory strategies, and commercialization pathways, fostering a collaborative environment for all attendees.

Advancements in Industry Collaboration

In his opening address, Tsingke Biotech's CEO, Shijin Ma, underscored the importance of collaborative efforts as China’s nascent nucleic acid industry transitions into a stage defined by innovation. Ma emphasized, "Open collaboration is essential for advancing nucleic acid therapeutics, which hinges on coordinated innovations across the entire supply chain. We aim to stimulate meaningful discussions through this forum."

The scientific agenda of the salon featured presentations from prominent figures in the field. Dr. Jun Bai, the Head of the Nucleic Acid Research Department at Haichang Biotech, discussed the evolution of small interfering RNA (siRNA) therapeutics. He highlighted advancements in conjugates and dual-targeting strategies that enhance drug effectiveness, particularly focusing on minimizing side effects and improving the precision of treatments.

Professor Qixian Chen, Chief Scientist at Tsingke Biotech and a distinguished academic at Zhejiang University, shared updates on the development of nucleic acid delivery methods that could overcome significant challenges in drug delivery. His findings revolved around innovative techniques aimed at targeting specific areas, including the central nervous system and tumor tissues.

In an exploration of the regulatory landscape, Dr. Yaning Wang, a former Director at the U.S. FDA and current Chief Scientific Advisor at Tsingke Biotech, reviewed pivotal case studies of FDA approvals, shedding light on the intricacies of scientific evidence generation and the factors influencing regulatory decisions.

A Comprehensive View of Drug Development

Dr. Chengjiang Zhao, Co-founder of Youjia Biotech, addressed critical aspects of Chemistry, Manufacturing, and Controls (CMC) during the candidate drug selection process. His insights centered around the significance of meticulous strategic planning to facilitate a smooth transition from candidate identification to the submission of an Investigational New Drug (IND).

Dr. Xichao Chen from Tsingke Biotech elaborated on the company’s integrated oligonucleotide drug development platform, detailing its capabilities in sequence design and optimization essential for the industrialization of oligonucleotide-based therapies.

Looking Towards the Future

The event featured a roundtable discussion with prominent voices from research, CMC development, and regulatory sectors, which emphasized the need for synergistic efforts in the sector’s ongoing maturation. Experts concurred that future competitiveness relies on an organization’s ability to harmonize scientific innovation with regulatory finesse and manufacturing prowess.

As one of the frontrunners in China’s nucleic acid industry, Tsingke Biotech is committed to fostering technological innovation. Their resources—including proprietary synthesis technology and quality control measures—are instrumental in advancing nucleic acid therapeutic development from initial discovery through commercial realization.

By harnessing cutting-edge advancements and collaborating with academic and industrial partners, Tsingke Biotech aims to accelerate the development of new therapies that will benefit patients worldwide. This commitment highlights Tsingke Biotech's role as a key player in the expanding field of small nucleic acid therapeutics, marking its impact in the global healthcare landscape.

For further updates, follow Tsingke Biotech on LinkedIn.